Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Ltd. has reported a significant 18% increase in Q1 2024 revenue, with total unaudited revenue reaching US$114.9M, driven by strong sales of its prostate cancer imaging product Illuccix. The company has also made strategic acquisitions to enhance its manufacturing capabilities and is on track for major milestones including drug approval submissions and trial expansions. Telix maintains a positive outlook for the full year, projecting a 35-40% revenue increase and a 40-50% boost in R&D investment.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
